Pictet Asset Management Holding SA Takes $17.80 Million Position in Novo Nordisk A/S $NVO

Pictet Asset Management Holding SA bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 1st quarter, HoldingsChannel reports. The firm bought 484,350 shares of the company’s stock, valued at approximately $17,800,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Franklin Resources Inc. raised its stake in shares of Novo Nordisk A/S by 4,190.8% during the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after purchasing an additional 13,658,867 shares during the period. Capital International Investors boosted its stake in shares of Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the period. Boston Partners acquired a new stake in Novo Nordisk A/S during the 3rd quarter valued at $310,199,000. Price T Rowe Associates Inc. MD grew its holdings in Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares in the last quarter. Finally, Voloridge Investment Management LLC increased its stake in Novo Nordisk A/S by 851.6% during the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after buying an additional 4,302,126 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Wolfe Research assumed coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. TD Cowen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a report on Tuesday, March 10th. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Five equities research analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Medicare is starting temporary coverage for GLP-1 obesity treatments, including Novo Nordisk’s Wegovy injection and tablet, which could broaden access and increase demand for the company’s weight-loss drugs. Medicare will start covering obesity drugs for the first time. Here’s what patients should know
• Positive Sentiment: Shantha Biologics announced an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India, a move that could help strengthen supply and support future product demand. Shantha Biologics Announces Cartridge Fill-Finish Collaboration
• Positive Sentiment: Nordea upgraded Novo Nordisk to Buy, signaling improved analyst confidence in the stock’s valuation and dividend appeal. Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why
• Positive Sentiment: Shares also rose after the company was highlighted as outperforming the broader market in recent trading, reflecting investor appetite for the name amid obesity-drug optimism. Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: News coverage around weight-loss ETFs and broader obesity-treatment investing reinforces sector interest, but it is more of a thematic tailwind than a direct catalyst for Novo Nordisk. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS estimate slightly, which is a modest cautionary note, though it did not change the broader longer-term growth story. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Novo Nordisk A/S Trading Up 1.6%

Novo Nordisk A/S stock opened at $48.69 on Thursday. The firm’s 50-day moving average is $44.25 and its 200-day moving average is $45.81. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $71.79. The company has a market cap of $217.40 billion, a P/E ratio of 11.43, a PEG ratio of 4.33 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. On average, equities analysts expect that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.